Bio-Plexus, Inc. and Premier Inc. Enter Into Agreement for Safety Blood Collection Products; Includes Complete Bio-Plexus Product Line.

Business Editors, Health/Medical Writers

Bio-Plexus, Inc. (OTCBB:BPXS), a leader in the design, manufacture and marketing of safety medical needles, today announced that it has entered into a multi-year agreement with Premier, Inc.

Premier is a national healthcare alliance that provides group purchasing services to approximately 1,600 not-for-profit hospitals.

Under the terms of the agreement, Premier's members will have access to all Bio-Plexus products beginning immediately. The products covered are the PUNCTUR-GUARD(R) safety blood collection products including Bio-Plexus' newest product, the PUNCTUR-GUARD(R) Winged Set for Blood Collection. This agreement follows an 18-month evaluation agreement with Premier during which time the Bio-Plexus safety products were evaluated by Premier member organizations.

Christopher Zorn, Executive Vice President of Sales at Bio-Plexus stated, "We are pleased to continue to work with one of the leading healthcare organizations in the country. Premier's approach to seeking out high quality safety technology for their members and their selection of Bio-Plexus as a quality vendor reinforces the Bio-Plexus reputation and mission of providing healthcare workers with a proven system for eliminating needlestick injuries. This agreement broadens our national scope and will immediately add significant new potential to our overall sales effort". Mr. Zorn continued, "The fact that our full catalog of safety needle products was included in the agreement is also important for Bio-Plexus. It is a testament to the quality of our products and recognizes our proven track record of customer support, service and dedication to Health Care Worker's safety."

About Premier Inc.

Premier is a leading healthcare alliance enterprise collectively owned by more than 200 independent not-for-profit hospitals and health systems in the United States. Together, they operate or are affiliated with more than 1,600 hospitals and other healthcare sites.

Premier's owners include some of the nation's largest and best-known not-for-profit hospital and healthcare systems and referral centers as well as strong community hospitals, generally mirroring the composition of the hospital/health system industry in the United States. For more information visit www.premierinc.com.

About Bio-Plexus

Bio-Plexus launched the PUNCTUR-GUARD(R) Winged Set for Blood Collection in July 2001. This followed the Company's receipt of 510(k) approval from the Food and Drug Administration in January 2001 and the successful clinical evaluations of the product undertaken by Bio-Plexus since May 2001. Winged sets are steel hollow bore needles with attached tubing used for blood collection. The PUNCTUR-GUARD Winged Set incorporates the same internal blunting technology used in the Company's PUNCTUR-GUARD multi-sample blood collection needle. Upon activation, an inner hollow blunt needle extends beyond the sharp point of the outer needle prior to removal of the device from the patient, thereby eliminating the exposure to sharp, contaminated needles. Current devices require removal of the contaminated sharp needle from the patient before the outer sheath can be moved into place over the contaminated needle.

Bio-Plexus, Inc., designs, develops, manufactures and holds U.S. and international patents on safety medical needles and other products under the PUNCTUR-GUARD(R), DROP-IT(R), and PUNCTUR-GUARD REVOLUTION(TM) brand names. For independent evaluations of the PUNCTUR-GUARD(R) blood collection needle, refer to the Centers for Disease Control (MMWR, January 1997) and ECRI (Health Devices, June 1998 and October 1999) studies. Accidental needlesticks number about one million per year in the United States and can result in the transmission of deadly diseases including HIV and Hepatitis B and C.

NOTE: MORE INFORMATION ABOUT THE COMPANY CAN BE FOUND IN ITS ANNUAL 2001 10K REPORT. THIS PRESS RELEASE CONTAINS FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. FORWARD-LOOKING STATEMENTS ARE IDENTIFIED BY THE USE OF SUCH TERMINOLOGY AS "BELIEVES," "EXPECTS," "MAY," "WILL," "SHOULD," "ANTICIPATES," "PLANS," "ESTIMATES," AND "INTENDS," OR DERIVATIONS OR NEGATIVES THEREOF, OR COMPARABLE TERMINOLOGY. ACCORDINGLY, SUCH STATEMENTS INVOLVE RISKS (KNOWN AND UNKNOWN) AND UNCERTAINTIES. The forward-looking statements are based on assumptions that the company believes are reasonable based on the best information currently available. However, there are a number of risks associated with these assumptions. THESE RISKS AND UNCERTAINTIES INCLUDE THE ABILITY TO MAINTAIN ITS CURRENT MONTHLY BURN RATE; THE EFFECT ON SUPPLIERS, CUSTOMERS, EMPLOYEES AND OTHERS; OF THE COMPANY'S RECEIPT OF A GOING CONCERN OPINION FROM ITS AUDITORS; THE EXTENT OF ACCEPTANCE OF THE COMPANY'S PRODUCTS BY HEALTH CARE PROFESSIONALS; THE COMPANY'S ABILITY TO PROTECT ITS PROPRIETY TECHNOLOGY; AVAILABILITY OF QUALIFIED PERSONNEL; CHANGES IN, OR FAILURE TO COMPLY WITH GOVERNMENT REGULATIONS; GENERAL ECONOMIC AND BUSINESS CONDITIONS; RELIANCE ON CERTAIN CRITICAL SUPPLIERS; AND OTHER RISK FACTORS AND UNCERTAINTIES DETAILED IN THIS REPORT, DESCRIBED FROM TIME TO TIME IN THE COMPANY'S OTHER SECURITIES AND EXCHANGE COMMISSION FILINGS, OR DISCUSSED IN THE COMPANY'S PRESS RELEASES. ALL FORWARD-LOOKING STATEMENTS INCLUDED IN THIS DOCUMENT ARE BASED ON INFORMATION AVAILABLE TO THE COMPANY ON THE DATE HEREOF, AND THE COMPANY ASSUMES NO OBLIGATION TO UPDATE OR ADVISE UPON ANY SUCH FORWARD-LOOKING STATEMENT.